Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,077 Mln
Revenue (TTM)
$4 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
76.8
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-22.8
Face value
--
Shares outstanding
153,032,000
CFO
$-34.61 Mln
EBITDA
$-75.97 Mln
Net Profit
$-120.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
180 Life Sciences (ATNF)
| 823.1 | 608.9 | 1,808.4 | 159.7 | -55.7 | -66.8 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
180 Life Sciences (ATNF)
| -54.9 | -93.7 | -95.7 | 42.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development... platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California. Read more
Co-Founder & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of 180 Life Sciences Corp (ATNF) is $16.80 (NASDAQ) as of 17-Oct-2025 09:30 EDT. 180 Life Sciences Corp (ATNF) has given a return of -55.75% in the last 3 years.
Since, TTM earnings of 180 Life Sciences Corp (ATNF) is negative, P/E ratio is not available.
The P/B ratio of 180 Life Sciences Corp (ATNF) is 76.81 times as on 17-Oct-2025, a 1849 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.29
|
0.19
|
|
2023
|
-0.01
|
-1.04
|
|
2022
|
-0.01
|
0.04
|
|
2021
|
-0.03
|
0.01
|
|
2020
|
0.00
|
0.00
|
The 52-week high and low of 180 Life Sciences Corp (ATNF) are Rs 17.45 and Rs 0.66 as of 03-Apr-2026.
180 Life Sciences Corp (ATNF) has a market capitalisation of $ 1,077 Mln as on 17-Oct-2025. As per SEBI classification, it is a Small Cap company.
Before investing in 180 Life Sciences Corp (ATNF), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$14.97
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.